Vaccines against Ebola virus and Marburg virus: recent advances …
WEBOct 7, 2019 · This vaccine includes Novavax, Inc.’s proprietary adjuvant Matrix-M, which has been shown to improve EBOV protective efficacy in mice 113 and NHPs. 114 Early safety and immunogenicity results from this trial are encouraging, as all vaccinees receiving the adjuvanted vaccine seroconverted. 114 The NHP and clinical study data suggest a …
Home | Novavax, Inc.
WEBUpdated Novavax COVID-19 vaccine (2024-2025 Formula) now available. Find Novavax's COVID-19 vaccine.
Ebola vaccine - Wikipedia
WEBAt the 8th Vaccine and ISV Conference in Philadelphia on 27−28 October 2014, Novavax Inc. reported the development in a "few weeks" of a glycoprotein (GP) nanoparticle Ebola virus (EBOV GP) vaccine using their proprietary recombinant technology.
Novavax's Ebola vaccine shows promise in early-stage trial
WEBJul 21, 2015 · Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults.
Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus
WEBJul 23, 2020 · Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.
The Matrix-M™ adjuvant: A critical component of vaccines for the 21
WEBApr 27, 2023 · Following the large Ebola outbreaks that occurred in several West African countries between 2013 and 2016, Novavax developed a recombinant Ebola virus (EBOV) GP nanoparticle vaccine formulated with Matrix-M. 27, 85 In BALB/c mice, EBOV GP co-administered with Matrix-M was significantly more immunogenic than GP co-administered with aluminum ...
Ebola Virus Disease Vaccines: Development, Current Perspectives ...
WEBJan 26, 2023 · The currently available vaccine candidates against EBOV virus include replicative vectored vaccines, non-replicative vectored vaccines, polypeptide vaccines, protein nanoparticle vaccines and DNA vaccines .
Current state of Ebola virus vaccines: A snapshot - PLOS
WEBDec 9, 2021 · Key benefits of virus-vectored vaccines are their ability to deliver antigen specifically to target cells and to induce robust, long-lived immunity. Ervebo, Zabdeno/Mvabea, and cAd3-EBOZ all express EBOV glycoprotein (GP) antigen to stimulate an immune response.
Novavax announces positive Phase 1 data for Ebola vaccine
WEBJul 22, 2015 · Novavax has announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™.
Novavax - Wikipedia
WEBNovavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.
- Some results have been removed
Skip to content